The UK’s medicines regulator, the MHRA, has approved the first GLP-1 receptor agonist tablet for weight loss. The drug is semaglutide, branded as Wegovy, and is authorized as a more convenient option than weekly injections, since it is taken as a daily tablet. Under the approval, Wegovy is available for adults who have obesity or who are overweight and have weight-related health conditions. Several reports say the change allows some patients to switch directly from the weekly injection to the 25 mg daily tablet. The Guardian also notes the UK is among the few countries that have authorized the treatment, stating it is the third country after the United States and the United Arab Emirates to approve the GLP-1 pill for weight loss. Other coverage indicates availability for patients is expected shortly following regulator approval, with timelines described as in the coming weeks. Together, the reports describe MHRA authorization as the key step enabling prescribing and access through criteria-based routes for eligible adults.